Home » Healthcare » Pharmaceuticals » Urinary Tract Infection (UTI) Treatment Market

Urinary Tract Infection (UTI) Treatment Market By Drug Type (Penicillin, Quinolones, Cephalosporin, Sulphonamides, Tetracycline, Other) – Growth, Future Prospects, and Competitive Analysis, 2017 – 2025

Price: $4999

Published: | Report ID: 11086 | Report Format : PDF

Market Insights:

Urinary tract infection (UTI) is the most common type of infection; it involves infection of the kidneys, ureters, bladder, or urethra. The UTI treatment market is rapidly growing due to factors such as the growing prevalence of UTI, significant unmet needs, and the rising number of drug-resistant bacteria due to excessive use of antibiotics.

Design Element 2

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

CTA Design Element 3

The report titled “Urinary Tract Infection (UTI) Treatment Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025” offers strategic insights into the overall UTI treatment market, along with the market size and estimates for the duration of 2015–2025. The research study covers an in-depth analysis of market segments based on drug class (penicillin, quinolones, cephalosporins, sulphonamides, tetracyclines, and others) and different geographical regions.

Geographically, the global UTI treatment market is studied for the following regional markets:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of LATAM
  • Middle East and Africa
    • GCC
    • the remainder of MEA

The market size and forecast for these regional and country-level markets are presented in this study for the period 2015–2025. Market growth rates for the forecast period 2017–2025 are also included in this report, considering 2016 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global UTI treatment market. Tools such as key player market positioning and an appealing investment proposition provide readers with insights into the global UTI treatment market’s competitive scenario. This report concludes with a company profiles section that highlights major information about the key players engaged in the global UTI treatment market. In-depth competitive environment analysis and historical year (2015) market size data are also provided in the report.

Thus, the research study provides a holistic view of the global UTI treatment market, offering market size and estimates for the period from 2015 to 2025, keeping in mind the above-mentioned factors.

Based on drug class, the global urinary tract infection (UTI) treatment market is segmented as follows:

  • Penicillin
  • Quinolones
  • Cephalosporin
  • Sulphonamides
  • Tetracycline
  • Other

Urinary tract infection (UTI) is the most common type of infection; it involves infection of the kidneys, ureters, bladder, or urethra. Some factors, such as the growing prevalence of UTI, the rising incidence of risk factors such as diabetes and kidney stones, early diagnosis of UTI, and changing lifestyle patterns, are prime factors that are driving the growth of the UTI treatment market globally. Drug resistance due to the excessive use of antibiotics and the increasing number of drug-resistant bacteria are other factors that would assist market growth during the forecast period. For the purpose of the study, the UTI treatment market is segmented on the basis of drug classes, such as penicillin, quinolones, cephalosporins, sulphonamides, tetracyclines, and others. It is observed that, in the base year 2016, demand for quinolones was highest on the market, as these are preferred as first-line treatment options due to their higher bioavailability and fewer side effects. Physicians generally prescribe a quinolone medicine if there are no other existing treatment options remaining for the treatment of a complicated UTI or kidney infection.

For the purpose of this study, the global urinary tract infection (UTI) treatment market is categorized into three segments:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Urinary tract infection (UTI) is one of the most common types of infections occurring in any part of the urinary tract, such as the ureters, kidneys, urethra, or bladder. According to the World Health Organization (WHO), approximately 50% of women report having a UTI at some point in their lives. Among the considered geographical segments, North America was a major revenue contributor in 2016. Early diagnosis, higher treatment awareness, swift adoption of novel medications, and better reimbursement policies in healthcare systems are the prime contributors to North America’s dominance. Higher expenditure on healthcare in the United States as compared to other nations is another factor contributing to market growth in North America. According to the Urology Foundation of America, 1 in 5 women will develop UTIs in their lifetime in America. However, due to rising healthcare awareness among the general patient population, a growing number of investments and partnerships between key players and local manufacturers are expected to assist the UTI treatment market’s growth in Asia-Pacific.

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Urinary Tract Infection (UTI) Treatment Market Snapshot
2.2 Global Urinary Tract Infection (UTI) Treatment Market, by Drug Class
2.3 Global Urinary Tract Infection (UTI) Treatment Market Share, by Geography, 2016 (Value %)

Chapter 3 Urinary Tract Infection (UTI) Treatment Market Analysis
3.1 Global Urinary Tract Infection (UTI) Treatment Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.2 Challenges
3.2.3 Opportunities
3.3 Attractive Investment Proposition
3.4 Competitive Landscape of Key Players in Urinary Tract Infection (UTI) Treatment Market
3.5 Top 3 Countries

Chapter 4 Global Urinary Tract Infection (UTI) Treatment Market, by Drug Class
4.1 Overview
4.2 Attractive Investment Proposition: Global Urinary Tract Infection (UTI) Treatment Market, by Drug Class
4.3 Penicillin
4.4 Quinolones
4.5 Cephalosporin
4.6 Sulphonamides
4.7 Tetracycline
4.8 Other

Chapter 5 Global Urinary Tract Infection (UTI) Treatment Market, By Geography
5.1 Preface
5.2 North America (U.S. & Canada)
5.2.1 North America Urinary Tract Infection (UTI) Treatment Market, by Drug Class, 2015- 2025 (US$)
5.2.2 North America Urinary Tract Infection (UTI) Treatment Market, by Country, 2015- 2025 (US$)
5.3 Europe (U.K., Germany & Rest of Europe)
5.3.1 Europe Urinary Tract Infection (UTI) Treatment Market, by Drug Class, 2015- 2025 (US$)
5.3.2 Europe Urinary Tract Infection (UTI) Treatment Market, by Country, 2015- 2025 (US$)
5.4 Asia Pacific (China, Japan and Rest of APAC)
5.4.1 Asia Pacific Urinary Tract Infection (UTI) Treatment Market, by Drug Class, 2015- 2025 (US$)
5.4.1 Asia Pacific Urinary Tract Infection (UTI) Treatment Market, by Country, 2015- 2025 (US$)
5.5 Latin America (Brazil, Mexico and Rest of LATAM)
5.5.1 Latin America Urinary Tract Infection (UTI) Treatment Market, by Drug Class, 2015- 2025 (US$)
5.5.2 Latin America Urinary Tract Infection (UTI) Treatment Market, by Country, 2015- 2025 (US$)
5.6 Middle East and Africa (GCC and Rest of MEA)
5.6.1 Middle East and Africa Urinary Tract Infection (UTI) Treatment Market, by Drug Class, 2015- 2025 (US$)
5.6.2 Middle East and Africa Urinary Tract Infection (UTI) Treatment Market, by Country, 2015- 2025 (US$)

Chapter 6 Company Profiles
6.1 AstraZeneca plc.
6.2 Bayer AG
6.3 Cubist Pharmaceuticals
6.4 F. Hoffmann–La Roche Ltd.
6.5 GlaxoSmithKline Pharmaceuticals Ltd.
6.6 Johnson & Johnson
6.7 MerLion Pharmaceuticals
6.8 Osel Inc.
6.9 Pfizer Inc.
6.10 Rempex Pharmaceuticals

List of Figures

FIG. 1 Urinary Tract Infection (UTI) Treatment Market: Research Methodology
FIG. 2 Global Urinary Tract Infection (UTI) Treatment Market, by Drug Class, 2016 (US$ Bn)
FIG. 3 Global Urinary Tract Infection (UTI) Treatment Market Share, by Geography, 2016 (Value %)
FIG. 4 Attractive Investment Proposition: Global Urinary Tract Infection (UTI) Treatment Market, by Geography, 2016
FIG. 5 Attractive Investment Proposition: Global Urinary Tract Infection (UTI) Treatment Market, by Drug Class, 2016
FIG. 6 Global Penicillin Market, 2015 – 2025 (US$ Bn)
FIG. 7 Global Quinolones Market, 2015 – 2025 (US$ Bn)
FIG. 8 Global Cephalosporin Market, 2015 – 2025 (US$ Bn)
FIG. 9 Global Sulphonamides Market, 2015 – 2025 (US$ Bn)
FIG. 10 Global Tetracycline Market, 2015 – 2025 (US$ Bn)
FIG. 11 Global Other Drugs in UTI treatment Market, 2015 – 2025 (US$ Bn)

List of Tables

TABLE 1 Market Positioning of Key Players in Global Urinary Tract Infection (UTI) Treatment Market
TABLE 2 Top 3 Countries in Global Urinary Tract Infection (UTI) Treatment Market
TABLE 3 Global Urinary Tract Infection (UTI) Treatment Market, by Drug Class, 2015 – 2025 (US$ Bn)
TABLE 4 Global Urinary Tract Infection (UTI) Treatment Market, by Geography, 2015 – 2025 (US$ Bn)
TABLE 5 North America Urinary Tract Infection (UTI) Treatment Market, by Drug Class, 2015-2025 (US$ Bn)
TABLE 6 North America Urinary Tract Infection (UTI) Treatment Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 7 Europe Urinary Tract Infection (UTI) Treatment Market, by Drug Class, 2015-2025 (US$ Bn)
TABLE 8 Europe Urinary Tract Infection (UTI) Treatment Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 9 Asia Pacific Urinary Tract Infection (UTI) Treatment Market, by Drug Class, 2015-2025 (US$ Bn)
TABLE 10 Asia Pacific Urinary Tract Infection (UTI) Treatment Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 11 Latin America Urinary Tract Infection (UTI) Treatment Market, by Drug Class, 2015-2025 (US$ Bn)
TABLE 12 Latin America Urinary Tract Infection (UTI) Treatment Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 13 Middle East and Africa Urinary Tract Infection (UTI) Treatment Market, by Drug Class, 2015-2025 (US$ Bn)
TABLE 14 Middle East and Africa Urinary Tract Infection (UTI) Treatment Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 15 AstraZeneca plc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 16 Bayer AG: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 17 Cubist Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 18 F. Hoffmann–La Roche Ltd.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 19 GlaxoSmithKline Pharmaceuticals Ltd.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 20 Johnson & Johnson: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 21 MerLion Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 22 Osel Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 23 Pfizer Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 24 Rempex Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)

Frequently Asked Questions:

What is the size of Urinary Tract Infection (UTI) Treatment Market?

The market for Urinary Tract Infection (UTI) Treatment is expected to reach US$ xx Bn in 2025.

What is the Urinary Tract Infection (UTI) Treatment Market CAGR?

The Urinary Tract Infection (UTI) Treatment market is expected to see significant CAGR growth over the coming years,at 3.2%.

What is the Forecast period considered for Urinary Tract Infection (UTI) Treatment Market?

The report is forecasted from 2017-2025.

What is the base year considered for Urinary Tract Infection (UTI) Treatment Market?

The base year of this report is 2016.

Who are the major players in this Market?

AstraZeneca plc., Bayer AG, Cubist Pharmaceuticals, F. Hoffmann–La Roche Ltd., GlaxoSmithKline Pharmaceuticals Ltd. are some of the major players in the global market.

U.S. 503b Compounding Pharmacies Market

Published:
Report ID: 15988

Inulin Market

Published:
Report ID: 11192

Drug Discovery Market

Published:
Report ID: 38270

Neurotrophic Keratitis Treatment Market

Published:
Report ID: 33425

Japan’s Pharmacy Automation Market

Published:
Report ID: 37511

Sterile Active Pharmaceutical Ingredient Market

Published:
Report ID: 37476

Organ Preservation Solutions Market

Published:
Report ID: 37472

Middle East and Africa Veterinary Vaccines Market

Published:
Report ID: 37309

Asia Pacific Stem Cell Therapy Market

Published:
Report ID: 37280

US Active Pharmaceutical Ingredient (API) Market

Published:
Report ID: 37221

Cancer Supportive Care Market

Published:
Report ID: 1901

Middle East and Africa Radiopharmaceuticals Market

Published:
Report ID: 37164

Purchase Options

$2999
Delivery Format: Excel.
$4999
Designed for the individual purchaser.
$6999
Users located at a single corporate site or regional office.
$7999
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN